BRAF and melanoma: As melanoma is frequently associated with oncogenic aberrations with BRAF mutations, drug development in the field of targeted therapies has arisen, first with the use of BRAF inhibitor (BRAFi) monotherapy (vemurafenib) in BRAF-mutated melanoma [6,12,13].